Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway

Fig. 1

The identification and affinity detection of SHH002-hu1. a. SDS-PAGE analysis of SHH002-hu1. Lane 1 represented non-reducing and lane 2 represented reducing condition. Lane M: Marker. b. SEC-HPLC analysis of SHH002-hu1. The peak shape of IPI control/SHH002-hu1chromatogram was presented well, and the baseline was stable. The criteria of system suitability was satisfied. c. Set of sensorgrams of rhFzd7 binding with SHH002-hu1 and SHH002. For SHH002-hu1, the association rate increased with increasing concentration of the rhFzd7 (from bottom to top: 6.25, 25, 100, 400 nmol/L). 0 s - 300 s: association, 300 s - 600 s: dissociation. For SHH002, the association rate increased with increasing concentration of the rhFzd7 (from bottom to top: 300, 750 nmol/L). 600 s - 1000 s: association, 1000 s - 1580 s: dissociation. d. Set of sensorgrams of rhFzd1/rhFzd2/rhFzd5/rhFzd8 protein binding with SHH002-hu1. 0 s - 300 s: association, 300 s - 600 s: dissociation. The association rate had no correlation with the concentration of rhFzd1/2/5/8. The red smooth curves in each figure represented the Fortebio fitting curves

Back to article page
\